Pharmacogenetics of bisphosphonates in osteoporosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bisphosphonates (BP) is - a class of drugs that exhibit high inhibitory activity to osteoclasts. BFs are the most effective drugs recommended for the treatment of osteoporosis (OP), which is one of the common diseases of bone tissue, when the risk of bone fracture is sharply increased either due to a decrease in the bone mineral density (BMD) or violation of its architectonics. However, there is growing evidence that the effectiveness of the use of BF does not demonstrate the expected results of treatment in a certain proportion of patients. In addition, it is difficult to predict the adverse responses of the body to these drugs based on the individual genetic profile of the patient, since significant differences in the results of global epidemiological and population studies are shown. Therefore, the systematization of research data in this area is relevant. The article will both describe the current state of the issue of the use of bisphosphonates in modern practice of treatment of OP, and summarize the current data on the pharmacogenetics of bisphosphonates.

Full Text

Restricted Access

About the authors

B. I Yalaev

Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of the Russian Academy of Sciences

Email: yalaev.bulat@yandex.ru

A. V Tyurin

Bashkir State Medical University

R. Z Nurlygayanov

City Clinical Hospital

R. I Khusainova

Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of the Russian Academy of Sciences

References

  1. Rinaldo Florencio-Silva, Gisela Rodrigues da Silva Sasso, Estela Sasso-Cerri, Simoes M.J., Cerri P.S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. BioMed Research International. 2015; 421746. https://doi.org/10.1155/2015/421746
  2. Meng-Xia Ji and Qi Yu. Primary osteoporosis in postmenopausal women. Chronic Diseases and Translational Medicine. 2015; 1 (1): 9-13. https://doi.org/10.10Wj. cdtm.2015.02.006
  3. Ralston S.H., Uitterlinden A.G. Genetic of osteoporosis. Endocrine Reviews. 2010; 31 (5): 629-62. https://doi.org/10.1210/er.2009-0044
  4. Kiel D.P, Demissie S., Dupuis J., Lunetta K.L., Murabito J.M., Karasik D. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Medical Genetics. 2007; 8 (1): 14. https://doi. org/10.1186/1471-2350-8-S1-S14
  5. Styrkarsdottir U., Halldorsson B.V., Gretarsdottir S., Gudbjartsson D.F., Walters G.B., Ingvarsson T., Jonsdottir T., Saemundsdottir J., Center J.R., Nguyen T.V, Bagger Y, Gulcher J.R., Eisman J.A., Christiansen C., Sigurdsson G., Kong A., Thorsteinsdottir U., Stefansson K. Multiple genetic loci for bone mineral density and fractures. The New England J. of Medicine. 2008; 358 (22): 2355-65. https://doi.org/10.1056/NEJMoa0801197
  6. Richards J.B., Rivadeneira F., Inouye M., Pastinen T.M., Soranzo N., Wilson S.G., Andrew T, Falchi M., Gwilliam R., Ahmadi K.R., Valdes A.M., Arp P, Whittaker P, Verlaan D.J., Jhamai M., Kumanduri V, Moorhouse M., van Meurs J.B., Hofman A., Pols H.A., Hart D., Zhai G., Kato B.S., Mullin B.H., Zhang F., Deloukas P, Uitterlinden A.G., Spector T.D. Bone mineral density, osteoporosis, and osteoporotic fracture: a genome-wide association study. Lancet. 2008; 371 (9623): 1505-12. https://doi.org/10.1016/S0140-6736(08)60599-1
  7. Rivadeneria F., Styrkarsdottir U., Estrada K., Halldorsson B.V, Hsu Y.H., Richards J.B., Zillikens M.C., Kavvoura F.K., Amin N., Aulchenko Y.S., Cupples L.A., Deloukas P, Demissie S., Grundberg E., Hofman A., Kong A., Karasik D., van Meurs J.B., Oostra B., Pastinen T, Pols H.A., Sigurdsson G., Soranzo N., Thorleifsson G., Thorsteinsdottir U., Williams F.M., Wilson S.G., Zhou Y., Ralston S.H., van Duijn C.M., Spector T, Kiel D.P, Stefansson K., loannidis J.P, Uitterlinden A.G. Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nature Genetics. 2009; 41 (11): 1199-206. https:// doi.org/10.1038/ng.446
  8. Zheng H.F., Spector T.D., Richards J.B. Insights into the genetics of osteoporosis from recent genome-wide association studies. Expert Reviews in Molecular Medicine. 2011; 13: e28. https://doi.org/10.1017/ S1462399411001980
  9. Karasik D., Rivadeneira F., Johnson M.L. The genetics of bone mass and susceptibility to bone diseases. Nature Reviews Rheumatology. 2016. 12 (6): 323-34. https://doi. org/10.1038/nrrheum.2016.48
  10. Makovey J., Nguyen T.V., Naganath V, Wark J.D., Sambrook PN. Genetic effects on bone loss in peri- and postmenopausal women: a longitudinal twin study. J. of Bone and Mineral Research. 2007; 22 (11): 177380. https://doi.org/10.1359/jbmr.070708
  11. Howard G.M., Nguyen T.V., Harris M., Kelly PJ., Eisman J.A. Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: twin study. Journal of Bone and Mineral Research. 1998; 13 (8): 1318-27. https://doi. org/10.1359/jbmr. 1998.13.8.1318
  12. Хусайнова РИ., Хуснутдинова Э.К. Генетика остеопороза. Уфа: Гилем, 2015; 392. [Khusainova R.I., Khusnutdinova Eh.K. Genetics of osteoporosis. Ufa: Gilem, 2015; 392 (in Russian)]
  13. Khosla S., Hofbauer L.C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5 (11): 898-907. https:// doi.org/10.1016/S2213-8587(17)30188-2
  14. Хоменко А.И., Лобко С.С. Бисфосфонаты в клинике лечения остеопороза. Медицинские новости. 2014; 7: 27-31.
  15. Скрипникова И.А., Косматова О.В., Абирова Э.С. Новиков В.Е., Мурашко Л.М. Опыт применения препарата Пролиа у пациенток с постменопаузальным остеопорозом в клинической практике. Терапевтический архив. 2017; 89 (12-2): 190-6. [Skripnikova I.A., Kosmatova O.V, Abirova E.S., Novikov V.E., Murashko L.M. Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice. Terapevticheskij arhiv 2017; 89 (12-2): 190-6 (in Russian)]
  16. Marie PJ. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Current Opinion in Rheumatology. 2006; 18 (1): S11e5.
  17. Лесняк О.М., Торопцова Н.В. Диагностика, лечение и профилактика остеопороза в общей врачебной практике. Российский семейный врач. 2014; 18 (4): 4-17. [Lesnyak O.M., Toropcova N.V Diagnosis, treatment and prevention of osteoporosis in general practice clinical guidelines. Rossijskij semejnyj vrach 2014; 18 (4): 4-17 (in Russian)]
  18. Беляева Е.А. Рациональный подход к выбору фармакотерапии при остеопорозе и коморбидных заболеваниях. Вестник новых медицинских технологий. 2012; 1: 1-9. [Belyaeva E.A. The rational approach to choice of pharmacotherapy at the osteoporosis and the comorbide diseases. Vestnik novyh medicinskih tekhnologij. 2012; 1: 1-9 (in Russian)]
  19. Беневоленская Л.И., Лесняк О.М. Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение. М.: ГЭОТАР-Медиа, 2005; 176. [Benevolenskaya L.I. Lesnyak O.M. Clinical recommendations. Osteoporosis. Diagnosis, prevention and treatment. M.: GEOTAR-Media, 2005; 175 (in Russian)]
  20. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., Kiel D., LeBoff M., Maricic M., Miller P, Moniz C., Peacock M., Richardson P, Watts N., Baylink D. A randomized trial of nasalspray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. The Am. J. of Medicine. 2000; 350: 459-468. htt-ps://doi.org/10.1016/s0002-9343(00)00490-3
  21. Mc Clung M.R., Wagman R.B., Miller PD., Wang A., Lewiecki E.M. Observations following discontinuation of long-term denosumab therapy. Osteoporosis International. 2017; 28 (5): 1723-32. https://doi. org/10.1007/s00198-017-3919-1
  22. Blessing A., Isiaka A. and Patricia P Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics. 2017; 9 (1): 2. https://doi. org/10.3390/pharmaceutics9010002
  23. Kavitha Ganesan, Douglas Roane. Bisphosphonate. Treasure Island (FL): Stat Pearls Publishing. 2019.
  24. Kristie N.T., Janette D.L., Chew K.V.W. Osteoporosis: A Review of Treatment Options. P&T. 2018; 43 (2): 92-104.
  25. Buhaescu I., Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clinical Biochemistry. 2007; 40 (9-10): 575-84. https://doi.org/10.10Wj. clinbiochem.2007.03.016
  26. Монахова А.И., Егорова Е.В., Лялина В.В., Сторожаков ГИ. Фармакогенетика бисфосфонатов в лечении постменопаузального остеопороза. Обзор литературы. Лечебное дело. 2013; 3: 53-8. [Monahova A.I., Egorova E.V., Lyalina V.V., Storozhakov G.I. Pharmacogenetics of Bisphosphonates in Postmenopausal Women with Osteoporosis. Literature Review. 2013; 3: 53-8 (in Russian)]
  27. John P.B., Lawrence G.R. and John T.M. Principles of Bone Biology. San Diego: Academic Press. 2008; 1943-72.
  28. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T, Hochberg M.C., Nevitt M.C., Suryawanshi S., Cummings S.R. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. The J. of Clinical Endocrinology & Metabolism. 2000; 85 (11): 4118-24. https://doi. org/10.1210/jcem.85.11.6953
  29. Black D.M, Reid I.R., Boonen S. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal: Internist (Berl). 2012; 27 (2): 243-54. https://doi.org/10.1002/ jbmr. 1542
  30. Marini F., Brandi M.L. Pharmacogenetics of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism. 2014; 28 (6): 783-93. https://doi.org/10.10Wj. beem.2014.07.004
  31. Palomba S., Numis F.G., Mossetti G., Rendina D., Vuotto P, Russo T, Zullo F., Nappi C., Nunziata V. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Human Reproduction. 2003; 18 (1): 192-8. https://doi.org/10.1093/hum-rep/deg031
  32. Palomba S., Orio F.J., Russo T., Falbo A., Tolino A., Manguso F., Nunziata V, Mastrantonio P, Lombardi G., Zullo F. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis International. 2005; 16 (8): 943-52. https://doi.org/10.1007/s00198 004-1800-5
  33. Marc J., Prezelj J., Komel R., Kocijancic. A. VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporosis International. 1999; 10 (4): 303-6. https://doi.org/10.1007/ s001980050231
  34. Mossetti G., Gennari L., Rendina D. Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. Calcified Tissue International. 2008; 83 (6): 414-24. https://doi.org/10.1007/ s00223-008-9193-7
  35. Corral-Gudino L., del Pino-Montes J., Garcia-Aparicio J. -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Bone. 2006; 38 (4): 589-94. https://doi.org/10.10Wj.bone.2005.09.010
  36. Valeria C., Giusy R., Graziamaria C., Giuseppe T., Vittorio S., Walter F., Nicola F., Michela G.,Valeria D' Argenio, Nicola M., Amelia F. A Polymorphism at the Translation Start Site of the Vitamin D Receptor Gene Is Associated with the Response to Anti-Osteoporotic Therapy in Postmenopausal Women from Southern Italy. International J. of Molecular Sciences. 2015; 16 (3): 545266. https://doi.org/10.3390/ijms16035452
  37. Крылов М.Ю., Никитинская О.А., Самаркина Е.Ю., Демин Н.В., Торопцова Н.В. Поиск генетических маркеров, определяющих эффективность терапии бисфосфонатами у российских женщин с постменопаузальным остеопорозом: пилотное исследование. Научно-практическая ревматология. 2016; 54 (4): 412-7. [Krylov M.Yu., Nikitinskaya O.A., Samarkina E.Yu., Demin N.V, Toroptsova N.V earch for genetic markers determining the efficiency of therapy with bisphosphonates in Russian women with postmenopausal osteoporosis: A pilot study. Nauchno-prakticheskaya revmatologiya 2016; 54 (4): 412-7 (in Russian)]
  38. Qureshi A.M., Herd R.J., Blake G.M., Fogelman I., Ralston H. COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcified Tissue International. 2002; 70 (3): 158-63. https://doi.org/10.1007/s00223-001-1035-9
  39. Meyer S., Haist M., Schaefer S., Ivan D., Ittner J.R., Nawroth P.P., Plockinger U., Stalla G.K., Tuschy U., Weber M.M., Weise A., Pfutzner A., Habbe N., Kann PH. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics. 2008; 9 (8): 1017-26. https://doi.org/10.2217/14622416.9.8.1017
  40. Marini F., Falchetti A., Silvestri S., Bagger Y, Luzi E., Tanini A., Christiansen C., Brandi M.L. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to longterm amino-bisphosphonate treatment in postmenopausal osteoporosis. Current Medical Research and Opinion. 2008; 24 (9): 2609-15. https://doi. org/10.1185/03007990802352894
  41. Choi H.J., Choi J.Y, Cho S.W., Kang D., Han K.O., Kim S.W., Kim S.Y., Chung YS., Shin C.S. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med. J. 2010; 51 (2): 231-8. https://doi.org/10.3349/ ymj.2010.51.2.231
  42. Liu Y, Liu H., Li M., Zhou P, Xing X., Xia W., Zhang Z., Liao E., Chen D., Liu J., Tao T., Wu W., Xu L. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Chinese Med. J. 2014; 127 (4): 662-8. https://doi.org/10.3760/ cma.j.issn.0366-6999.20132382
  43. Songpatanasilp T., Chanprasertyothin S. Effects of differences in polymorphism of gene encoding enzyme farnesyl diphosphate synthase (FDPS), rs2297480, on bone mineral density and biochemical markers of bone turnover in Thai postmenopausal women. J. of the Medical Association of Thailand. 2011; 94 (5): 38-46
  44. Francisco-Javier Rodriguez-Lozano and Ricardo-Elias Onate-Sanchez. Treatment of osteonecrosis of the jaw related to bispho-sphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal. 2016; 21 (5): 595-600. https://doi.org/10.4317/me-doral.20980
  45. Hiromitsu Kishimoto, Kazuma Noguchi, and Kazuki Takaoka. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Japanese Dental Science Review. 2019; 55 (1): 95-102. https://doi.org/10.10Wj.jdsr.2018.09.002
  46. Di Martino M.T., Arbitrio M., Guzzi PH., Emanuela L., Francesco B., Eugenio P, Tullia P, Iole C., Teresa C., Marco R., Pierangelo V, Mario C., Pierosandro T, Pierfrancesco T. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: Analysis by DMET microarray profiling. British J. of Haematology. 2011; 154 (4): 529-33. https:// doi.org/10.1111/j.1365-2141.2011.08622.x
  47. Katz J., Gong Y, Salmasinia D., Hou W., Burkley B., Ferreira P, Casanova O., Langaee T.Y., Moreb J.S. Genetic polymorphisms and other risk factors associated with bisphos-phonate induced osteonecrosis of the jaw. International J. of Oral and Maxillofacial Surgery. 2011; 40 (6): 605-11. https://doi. org/10.1016/j.ijom.2011.02.002
  48. Sarasquete M.E., Garcia-Sanz R., Marin L., Alcoceba M., Chillon M.C., Balanzategui A., Santamaria C., Rosinol L, de la Rubia J., Hernandez M.T., Garcia-Navarro I., Lahuerta J.J., Gonzalez M., San Miguel J.F Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008; 112 (7): 2709-12. https://doi. org/10.1182/blood-2008-04-147884
  49. Nicoletti P, Cartsos V.M., Palaska PK., Shen Y, Floratos A., Zavras A. Genome wide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist. 2012; 17 (2): 279-87. https://doi.org/10.1634/theoncologist.2011-0202
  50. Hanh H.N., Denise M. van de Laarschot, Annemieke J.M.H. Verkerk, Frances M., M. Carola Zillikens, Peter R. Ebeling Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review. JBMR Plus. 2018; 2 (1): 1-11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies